SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ware S, Millward-Sadler GH. Acute liver failure associated with sodium valproate. Lancet 1980;2:111032.
  • 2
    Sleiman C, Raffy O, Roué C, Mal H. Fatal pulmonary hemorrhage during high-dose valproate monotherapy. Chest 2000;117:613.
  • 3
    Rajantie J, Kajosaari M, Ylitalo V. Fatal pancytopenia during high-dose valproate monotherapy (letter). Eur J Pediatr 1992;151:619.
  • 4
    Kaya IS, Dilmen U, Toppare M, et al. Valproic-acid-induced pancytopenia and Coombs test positivity. Lancet 1991;337:12278.
  • 5
    Ward MW, Barbaro NW, Laxer KD, et al. Preoperative valproate administration does not increase blood loss during temporal lobectomy. Epilepsia 1996;37:98101.
  • 6
    Anderson G, Lin YX, Berge C, et al. Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J Neurosurg 1997;87:2526.
  • 7
    Koch-Weser J, Browne TR. Drug therapy: valproic acid. N Engl J Med 1980;302:6616.
  • 8
    Schmidt D. Adverse effects of valproate. Epilepsia 1984;25:449.
  • 9
    Allen GC, Armfield DR, Bontempo FA, et al. Adenotonsillectomy in children with von Willebrand disease. Arch Otolaryngol Head Neck Surg 1999;125:54751.
  • 10
    Chambers HG, Weinstein CH, Mubarak SJ, et al. The effect of valproic acid on blood loss in patients with cerebral palsy. J Pediatr Orthop 1999;19:7925.
  • 11
    Winter SL, Kriel NL, Novacheck TF, et al. Perioperative blood loss: the effect of valproate. Pediatr Neurol 1996;15:1922.
  • 12
    Loiseau P. Sodium valproate, platelet dysfunction and bleeding. Epilepsia 1981;22:1416.
  • 13
    Gidal B, Spencer N, Maly M, et al. Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration. Neurology 1994;44:141822.
  • 14
    Eastham RD, Jancar J. Letter: Sodium valproate and platelet counts. Br Med J 1980;280:186.
  • 15
    Von Czettritz G, Weinmann HM. Gerinnungsstörung unter Valproinsäure. In: KrämerG, LaubM, eds. Valproinsäure. Heidelberg : Springer-Verlag, 1992:2106.
  • 16
    Zeller JA, Schlesinger S, Runge U, et al. Influence of valproate monotherapy on platelet activation and hematologic values. Epilepsia 1999;40:1869.
  • 17
    Hauser E, Seidl R, Freilinger M, et al. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev 1996;18:1059.
  • 18
    May RB, Sunder TR. Hematologic manifestations of long-term valproate therapy. Epilepsia 1993;34:1098101.
  • 19
    Barr RD, Copeland SA, Stockwell ML, et al. Valproic acid and immune thrombocytopenia. Arch Dis Child 1982;57:6814.
  • 20
    Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982;23:693720.
  • 21
    Neophytides AN, Nutt JG, Lodish JR. Thrombocytopenia associated with sodium valproate treatment. Ann Neurol 1979;5:38990.
  • 22
    Krause KH. Thrombozytenwerte bei Erwachsenen unter Behandlung mit DPA (Ergenyl). Med Welt 1977;28:10989.
  • 23
    Tanindi Ş, Akin R, Köseoğlu, et al. The platelet aggregation in children with epilepsy receiving valproic acid. Thromb Res 1996;81:4716.
  • 24
    Delgado MR, Riela AR, Mills J, et al. Thrombocytopenia secondary to high valproate levels in children with epilepsy. J Child Neurol 1994;9:3114.
  • 25
    Watts RG, Emanuel PD, Zuckerman KS, et al. Valproic acid-induced cytopenias: evidence for a dose related suppression of hematopoiesis. J Pediatr 1990;117:4959.
  • 26
    Ganick DJ, Sunder T, Finley JL. Severe hematologic toxicity of valproic acid: a report of four patients. Am J Pediatr Hematol Oncol 1990;12:805.
  • 27
    Sherbany AA, Rothman SJ, Jayabose S. Delayed-onset dose-related valproate-induced thrombocytopenia. Neurology 1990;40:137.
  • 28
    Cheng RD, Kohrman MH, Kerr SL, et al. Thrombocytopenia associated with valproic acid that requires platelet transfusion. Ann Neurol 1989;26:4578.
  • 29
    Smith FR, Boots M. Sodium valproate and bone marrow suppression. Ann Neurol 1980;8:1979.
  • 30
    Sutor AH, Jesdinsky-Buscher C. (Alteration of hemostasis during anticonvulsive Therapy with dipropyl-acetate (DPA), further observations). Fortschr Med 1976;94:4114.
  • 31
    Kishi T, Fujita N, Kawaguchi H, et al. Bone marrow suppression induced by high dose valproic acid. Arch Dis Child 1994;71:1535.
  • 32
    Stahl MMS, Neiderud J, Vinge E. Thrombocytopenic purpura and anemia in a breast-fed infant whose mother was treated with valproic acid. J Pediatr 1997;130:10013.
  • 33
    Bruni J, Wilder BJ. Valproic acid: review of a new antiepileptic drug. Arch Neurol 1979;53:7380.
  • 34
    Sandler RM, Emberson C, Roberts GE, et al. IgM platelet auto-antibody due to sodium valproate. Br Med J 1978;2:16834.
  • 35
    Tetzlaff JE. Intraoperative defect in haemostasis in a child receiving valproic acid. Can J Anaesth 1991;38:2224.
  • 36
    Keenan JP, Wharton J, Sheperd AJN, et al. Defective platelet lipid peroxidation in myeloproliferative disorders: a possible defect of prostaglandin synthesis. J Haematol 1977;35:275.
  • 37
    Von Hoss H, Schulte-Berbühl R, Göbel U. Side effects of sodium valproate (sodium di-N-propylacetate) on malonyldialdehyde-production and other platelet function tests. Min Pediatr 1978;30:1397404.
  • 38
    Kis B, Szupera Z, Mezei Z, et al. Valproate treatment and platelet function: the role of arachidonate metabolites. Epilepsia 1999;40:30710.
  • 39
    Ozkara C, Dreifuss FE, Apperson Hansen C. Changes in red blood cells with valproate therapy. Acta Neurol Scand 1993;88:2102.
  • 40
    König SA, Siemes H, Blaker F, et al. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 1994;35:100515.
  • 41
    Kreuz W, Mentzer D, Becker S, et al. Haemate P in children with von Willebrand's disease. Haemostasis 1994;24:30410.
  • 42
    Corrigan JJ. Hemorrhagic and thrombotic diseases. In: NelsonWE, BehrmanRE, KliegmanRM, et al., eds. Textbook of pediatrics, 15th ed. London : WB Saunders, 1996:142238.
  • 43
    Gil-Fernandez JJ. Letter to editor. Epilepsia 1997;38:12578.
  • 44
    Koscielny J, Blaicher AM, Felfernig D, et al. Consensus use of desmopressin and antifibrinolytics in three university clinics. Anaesthesia 1998;53:602.
  • 45
    Lethagen S. Desmopressin: a hemostatic drug: state-of-the-art review. Eur J Anaesthesiol 1997;14:19.
  • 46
    Lethagen S, Frick K, Sterner G. Antidiuretic effect of desmopressin given in hemostatic dosages to healthy volunteers. Am J Hematol 1998;57:1539.
  • 47
    Croiset G, De Wied D. Proconvulsive effect of vasopressin: mediation by a putative V2 receptor subtype in the central nervous system. Brain Res 1997;759:1823.
  • 48
    Bernstein SA, Williford SL. Intranasal desmopressin-associated hyponatremia: a case report and literature review. J Fam Pract 1997;44:2038.
  • 49
    Apakama DC, Bleetman A. Hyponatraemic convulsion secondary to desmopressin treatment for primary enuresis. J Accid Emerg Med 1999;16:22930.
  • 50
    Schwab M, Wenzel D, Ruder H. Hyponatraemia and cerebral convulsion due to short term DDAVP therapy for control of enuresis nocturna. Eur J Pediatr 1996;155:468.
  • 51
    Frölich J, Wiater A. (Hyponatremia with cerebral convulsions: complications of a treatment of enuresis nocturna with desmopressin). Monatsschr Kinderheilkd 2000;148:76870.
  • 52
    Heene DL, Matthias FR. Koagulopathien. In: BegemannH, RastetterJ, eds. Klinische Hämatologie. 4th ed. Stuttgart : Georg Thieme Verlag, 1993:82869.
  • 53
    Anai T, Hirota Y, Oga M, et al. PIVKA II (protein induced by vitamin K absence-II) status in newborns exposed to anticonvulsant drugs in utero [Abstract]. Nippon Sanka Fujinka Gakkai Zasshi 1991;43:34750.
  • 54
    Cornelissen M, Steegers-Theunissen R, Kollee L, et al. Increased incidence of neonatal vitamin K deficiency resulting from maternal anticonvulsant therapy. Am J Obstet Gynecol 1993;168:9238.
  • 55
    Thomas L. Hämostase bei Kindern, Schwangeren und bestimmten Erkrankungen. In: ThomasL, ed. Labor und Diagnose. Frankfurt/Main : TH-Books Verlagsgesellschaft mbH , 1998:6006.
  • 56
    Fickenscher K. Gerinnungsfaktoren-Einzelanalysen. In: ThomasL, ed. Labor und Diagnose. Frankfurt/Main : TH-Books Verlagsgesellschaft mbH , 1998:6214.
  • 57
    Rothschild BM. Hematologic perturbations associated with salicylate. Clin Pharmacol Ther 1979;26:14552.
  • 58
    Zaugg H. Sind salicylartige Analgetika Vitamin K-Antagonisten? Eine Deutung der spontanen subnormalen Quickwerte. Schweiz Med Wschr 1978;108:12778.
  • 59
    Mountain KR, Hirsch J, Gallus AS. Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy. Lancet 1970;1:2658.
  • 60
    Yerby MS. Risks of pregnancy in women with epilepsy. Epilepsia 1992;33:237.
  • 61
    Rochel M, Ehrenthal W. Haematological side effects of valproic acid. In: OxleyJ, ed. Chronic toxicity of antiepileptic drugs. New York : Raven Press, 1983:1013.
  • 62
    Cordes I, Buchmann S, Scheffner D. (Vitamin K deficiency under treatment with erythromycin. Clinical course of a boy treated with valproic acid). Monatsschr Kinderheilkd 1990;138:857.
  • 63
    Tam DA, Myer EC. Vitamin K-dependant coagulopathy in a child receiving anticonvulsant therapy. J Child Neurol 1996;11:2446.
  • 64
    Frick PG, Riedler G, Brogli H. Response and minimal daily requirement for vitamin K in man. J Appl Physiol 1967;23:387.
  • 65
    Bayer W, Schmidt K. Vitamin K. In: BayerW, SchmidtK, eds. Vitamine in Prävention und Therapie. Stuttgart : Hippokrates-Verlag, 1991:89102.
  • 66
    Bechtold H, Andrassy K. Vitamin K und medikamenteninduzierte Hypoprothrombinämie. Hämostaseologie 1988;8:817.
  • 67
    Scott AK, Haynes BP, Schinkel KD, et al. Hepatic enzyme induction and vitamin K1 elimination in man. Eur J Clin Pharmacol 1987;33:935.
  • 68
    Mc Burney A, Shearer MJ, Barkhan P. Preparative isolation and characterization of the urinary aglycones of vitamin K1 (phylloquinone) in man. Biochem Med 1980;24:25067.
  • 69
    Wagner C, Dato F. Fibrinogen. In: ThomasL, ed. Labor und Diagnose. Frankfurt/Main : TH-Books Verlagsgesellschaft mbH , 1998:6247.
  • 70
    Echinaz-Laguna A, Thiriaux A, Ruolt-Olivesi I, et al. Lupus anticoagulant induced by the combination of valproate and lamotrigine. Epilepsia 1999;40:16613.
  • 71
    Gadner H, Bensel I, Grimm B, et al. Beeinflussung der Hämostase durch Dipropylessigsäure. Monatsschr Kinderheilkd 1976;124:4489.
  • 72
    Majer RV, Green PJ. Neonatal afibrinogenaemia due to sodium valproate. Lancet 1987;2:7401.
  • 73
    Dale BM, Purdie GH, Rischbieth RH. Fibrinogen depletion with sodium valproate. Lancet 1978;17:13167.
  • 74
    Monnet P, David M, Philippe N, et al. Altérations de l'hémostase lors des traitements au dipropylacetate de sodium. Pédiatrie 1979;34:60320.
  • 75
    Bavoux F, Fournier-Perhilou AI, Wood C, et al. Neonatal fibrinogen depletion caused by sodium valproate. Ann Pharmacother 1994;28:1307.
  • 76
    Tokuda K, Kodani N, Ogino T. Three cases of hypofibrinogenemia induced by chemotherapy with a combination of synthetic ACTH and valproic acid [Abstract]. No To Hattatsu 1994;26:506.
  • 77
    Ojemann LM, Wilensky AJ, Temkin NR, et al. Fibrinogen and valproic acid. Epilepsia 1981;22:2423.
  • 78
    Fickenscher K. Faktor XIII. In: ThomasL, ed. Labor und Diagnose. Frankfurt/Main : TH-Books Verlagsgesellschaft mbH , 1998:6278.
  • 79
    Nicholson JF, Pesce MA. Laboratory medicine and reference tables. In: NelsonWE, BehrmanRE, KliegmanRM, et al., eds. Textbook of pediatrics. 15th ed. London : WB Saunders, 1996:203184.
  • 80
    Thies HA, Richter H. Erworbener Faktor XIII-Mangel und klinische Chirurgie. Med Welt 1981;32:2505.
  • 81
    Tilsner V. Blutungskomplikationen in der perioperativen Phase. In: MammenEF, ed. Intensivmedizin aktuell. Marburg : Medizinische Verlagsgesellschaft , 1987:3245.
  • 82
    Pohlmann-Eden B, Peters CN, Wennberg R, et al. Valproate induces reversible factor XIII deficiency with risk of perioperative bleeding. Acta Neurol Scand 2003;108:1425.